Ignite Creation Date:
2024-05-05 @ 11:34 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00086606
Status:
TERMINATED
Last Update Posted:
2013-01-21
First Post:
2004-07-06
Brief Title:
A Safety and Efficacy Study of Xolair in Peanut Allergy
Sponsor:
Genentech Inc
Organization:
Genentech Inc
Study Overview
Official Title:
A Phase II Randomized Double-Blind Parallel-Group Placebo-Controlled Oral Food Challenge Trial of Xolair Omalizumab in Peanut Allergy
Status:
TERMINATED
Status Verified Date:
2013-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a 38-week randomized double-blind placebo-controlled parallel group trial of approximately 150 patients who have a history of immediate hypersensitivity reaction to peanut protein
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None